AVERT-DOSE (Determining Optimal Early Rehabilitation After StrokE): A Multi-arm Covariate-adjusted, Response-adaptive Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$4,359,564.00
Summary
AVERT-DOSE is an international, investigator-led clinical trial, developed in Australia but recruiting >2500 patients from 6 countries around the world. In this trial we will establish the optimal model of early mobility rehabilitation for people with acute stroke. The protocols we develop will be suitable for adoption in clinical practice in developed and developing countries and help reduce the unacceptably high personal and community burden of stroke-related disability world wide.
Aboriginal And Torres Strait Islander Health Workers’ And Liaison Officers’ Role In Quality Acute Health Care Services
Funder
National Health and Medical Research Council
Funding Amount
$1,571,334.00
Summary
This project will explore the role of and give voice to Aboriginal and Torres Strait Islander Health Workers and Liaison Officers in acute health care services (hospitals), from the point of view of Aboriginal and Torres Strait Islander people who use health care (patients) and the health professionals who work with them. The project team will explore these issues using interviews, patient journeys and surveys across three hospitals.
AVERT: A Large, International, Randomised Controlled Trial Testing Efficacy And Cost Effectiveness Of Early And Frequent Mobilisation After Stroke
Funder
National Health and Medical Research Council
Funding Amount
$2,020,623.00
Summary
AVERT is a large, international clinical trial that tests whether introducing early and frequent exercise helps reduce the unacceptably high burden of death and disability associated with stroke. We are also testing if the intervention is cost effective. This trial will provide reliable evidence to guide clinical practice. If positive, broad implementation in both developed and developing countries is likely, thus helping to reduce the global burden of stroke related death and disability.
Pharmaceutical Opioid Prescription For Chronic Pain In Australia: Trajectories Of Prescribing, Risk Of Adverse Events, And Predictors Of Harm
Funder
National Health and Medical Research Council
Funding Amount
$1,086,274.00
Summary
There is concern about rising levels of opioid analgesic prescribing in Australia. This study is important because it will provide evidence about long term outcomes for patients using opioid therapy for chronic non-malignant pain. It will examine prescribing patterns and link them to other health outcomes such as overdose. We will also study patients beginning opioid therapy for chronic pain and follow them up over 2 years to examine outcomes such as pain relief and medication side effects.
Venesection Or Expectant Management For Moderate Iron Overload In HFE Related Hereditary Haemochromatosis
Funder
National Health and Medical Research Council
Funding Amount
$853,109.00
Summary
Haemochromatosis is a preventable genetic iron overload disorder. Untreated, it can shorten life due mainly to liver cirrhosis and cancer. It can be prevented by blood donation to maintain normal iron levels. It is unclear, however, whether treatment is necessary when individuals have moderate elevation of iron in the body. This research project will study the effects of treatment in this group by assessing a number of scans, questionnaires and blood tests in treated and untreated individuals.
Which Heart Failure Intervention Is Most Cost Effective In Reducing Hospital Care (WHICH? II) Trial: A Multicentre, Randomised Trial Of Standard Versus Intensified Management Of Metropolitan And Regional-dwelling Patients With Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$1,891,210.00
Summary
Chronic heart failure (CHF) management programs are now the gold-standard to cost-effectively care for thousands of Australians hospitalised with CHF each year. We’ve shown that home-based management is most cost-effective in reducing hospital stay in CHF. The Which Intervention is most Cost-effective in reducing Hospital care (WHICH? II) Trial, a multicentre, randomised study, will determine if more intensive care (via home visits and remote care contacts) further improves poor outcomes in CHF.
Investigating The Role Of Mutant P53 And MCL-1 In The Sustained Growth Of MYC Lymphomas And Strategies For Targeted Therapy
Funder
National Health and Medical Research Council
Funding Amount
$616,940.00
Summary
A large number of human cancers have abnormal expression of a protein called MYC, leading to rapid growth. We found that when another protein called MCL-1 was inactivated, the lymphomas regressed. Importantly, mutations in the tumour suppressor gene called p53 are frequently found in cancer cells and we noticed that this could reduce the dependency on MCL-1. We aim to investigate this further in this grant proposal, in part using a novel drug that targets MCL-1.
Structural Investigations Of The Bax And Bak Cell Death Apparatus
Funder
National Health and Medical Research Council
Funding Amount
$275,509.00
Summary
Programmed cell death is a process by which the body keeps rogue cells in check. Cancer cells adapt to avoid this process and thus evade this important defence mechanism. This project seeks to understand the machinery that controls programmed cell death at the molecular level. It will provide the atomic details of how this machinery is regulated and how it functions to induce cell death. These insights will provide new avenues for targeting this machinery for a new generation of cancer therapeut ....Programmed cell death is a process by which the body keeps rogue cells in check. Cancer cells adapt to avoid this process and thus evade this important defence mechanism. This project seeks to understand the machinery that controls programmed cell death at the molecular level. It will provide the atomic details of how this machinery is regulated and how it functions to induce cell death. These insights will provide new avenues for targeting this machinery for a new generation of cancer therapeutics.Read moreRead less
The Axis Of Bcl-2, Plasmacytoid DCs And Lupus As A Basis For Therapy
Funder
National Health and Medical Research Council
Funding Amount
$712,172.00
Summary
Systemic lupus erythematosus (SLE) affects 1 in 1000 Australians, mostly women. Here the immune system goes awry and makes antibodies against the body’s own components including the body’s DNA. This leads to damage to many parts of the body including kidneys, joints, brain and heart. It is incurable. A particular immune cell controls the development of this disease and we have found this cell is selectively killed by an inexpensive drug, which we hope will be a better way of treating SLE.
Health Impacts Of Climate Change On Indigenous Australians: Identifying Climate Thresholds To Enable The Development Of Informed Adaptation Strategies
Funder
National Health and Medical Research Council
Funding Amount
$361,034.00
Summary
Closing the gap in Indigenous health and adapting to climate change are two major policy challenges for Australia. This project addresses these issues by providing quantitative and qualitative evidence of the disproportionate impacts of climate on the health of Indigenous people. This research will provide policy-relevant evidence to enable targeting of resources to develop effective climate adaptation strategies to reduce adverse health outcomes for Indigenous Australians from climate change.